Subscribe to stay informed!
Malvern-based Ocugen saw its stock soar after the FDA lifted its clinical hold on the company’s investigational new drug application to test the…
Malvern-based Ocugen has submitted a request to the Food and Drug Administration for Emergency Use Authorization (EUA) of its COVID-19 vaccine candidate for…
Malvern-based Ocugen submitted an investigational new drug application with the FDA. It seeks approval to start a Phase-3 clinical trial that would evaluate…
Malvern-based Ocugen has encountered a significant obstacle in its plans to bring the COVID-19 vaccine developed in India to the U.S., writes…
Later this month, Malvern-based Ocugen will seek an emergency-use authorization from the FDA to cooperate with Bharat Biotech for the India-based company…
Malvern-based Ocugen’s stock increased nearly 201 percent after announcing its plans for a direct stock offering worth $23 million, writes John George for…
The decision to expand beyond gene therapy and sign a deal to co-develop a COVID-19 vaccine has turned out well for Malvern-based…
Malvern-based Ocugen saw its stock nearly triple last week after the company signed a letter of intent with Bharat Biotech to co-develop the…
Before we send you to this site, please subscribe to our daily newsletter.